Unlimited generation of chimeric antigen receptor (CAR) T cells from human-induced pluripotent stem cells (iPSCs) is an attractive approach for "off-the-shelf" CAR T cell immunotherapy. Approaches to efficiently differentiate iPSCs into canonical αβ T cell lineages, while maintaining CAR expression and functionality, however, have been challenging. We report that iPSCs reprogramed from CD62L+ naive and memory T cells followed by CD19-CAR engineering and 3D-organoid system differentiation confers products with conventional CD8αβ-positive CAR T cell characteristics. Expanded iPSC CD19-CAR T cells showed comparable antigen-specific activation, degranulation, cytotoxicity, and cytokine secretion compared with conve...
Background: Current advancements in the field of chimeric antigen receptor (CAR) therapy, particular...
Adoptive cell therapy, especially chimeric antigen receptor (CAR) therapy, has revolutionized cancer...
Abstract Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell...
Progress in adoptive T-cell therapy for cancer and infectious diseases is hampered by the lack of re...
The generation of immune cells from human pluripotent stem cells (embryonic stem cells and induced p...
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own imm...
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming...
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming...
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has...
Using induced pluripotent stem cells (iPSCs) to derive chimeric antigen receptor-modified T (CAR-T) ...
Chimeric antigen receptors (CARs) against CD19 have been shown to direct T-cells to specifically tar...
T cells and Type 2 innate lymphoid cells (ILC2) are closely related lymphoid lineages which share ce...
Although remarkable results have been attained by adoptively transferring TÂ cells expressing fully ...
Using induced pluripotent stem cells (iPSCs) to derive chimeric antigen receptor-modified T (CAR-T) ...
Abstract Hematopoietic stem cell‐ (HSC) and induced pluripotent stem (iPS) cell‐derived natural kill...
Background: Current advancements in the field of chimeric antigen receptor (CAR) therapy, particular...
Adoptive cell therapy, especially chimeric antigen receptor (CAR) therapy, has revolutionized cancer...
Abstract Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell...
Progress in adoptive T-cell therapy for cancer and infectious diseases is hampered by the lack of re...
The generation of immune cells from human pluripotent stem cells (embryonic stem cells and induced p...
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own imm...
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming...
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming...
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has...
Using induced pluripotent stem cells (iPSCs) to derive chimeric antigen receptor-modified T (CAR-T) ...
Chimeric antigen receptors (CARs) against CD19 have been shown to direct T-cells to specifically tar...
T cells and Type 2 innate lymphoid cells (ILC2) are closely related lymphoid lineages which share ce...
Although remarkable results have been attained by adoptively transferring TÂ cells expressing fully ...
Using induced pluripotent stem cells (iPSCs) to derive chimeric antigen receptor-modified T (CAR-T) ...
Abstract Hematopoietic stem cell‐ (HSC) and induced pluripotent stem (iPS) cell‐derived natural kill...
Background: Current advancements in the field of chimeric antigen receptor (CAR) therapy, particular...
Adoptive cell therapy, especially chimeric antigen receptor (CAR) therapy, has revolutionized cancer...
Abstract Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell...